GT Biopharma, Inc. (GTBP): Nasdaq/NYSE listing notice — GT Biopharma gets Nasdaq extension to Feb 20, 2024 for bid price compliance

GT Biopharma, Inc.

Company has until Feb 20, 2024 to close at $1.00 for 10 consecutive days to regain compliance.
May consider a reverse stock split to meet the Minimum Bid Price Requirement.
No immediate effect on listing; common stock continues trading on Nasdaq Capital Market under GTBP.
No assurance that compliance will be regained; company will monitor bid price and consider options.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

GT Biopharma, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

August 22, 2023, GT Biopharma, Inc. (the “Company”) received notice from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) advising that the Staff determined the Company is eligible for an additional 180 calendar day period, or until February 20, 2024, to regain compliance with its minimum bid price requirement rule under Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) pursuant to the Nasdaq Listing Rule 5810(c)(3)(A). The notification has no immediate effect on the listing of the Company’s common stock, and its common stock will continu

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

GT Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-029841

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.